Reversing the Inflammatory Process—25 Years of Tumor Necrosis Factor-α Inhibitors

KN Muth, J Rech, FO Losch, A Hoerning - Journal of Clinical Medicine, 2023 - mdpi.com
Immune-mediated inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis,
peripheral and/or axial spondyloarthritis, Crohn's disease, and ulcerative colitis, are …

The Management of Postoperative Recurrence in Crohn's Disease

E Fasulo, F D'Amico, L Osorio, M Allocca… - Journal of Clinical …, 2023 - mdpi.com
Crohn's disease (CD) is a chronic inflammatory bowel disease with different phenotypes of
presentation, inflammatory, penetrating, or stricturing disease, that significantly impacts …

Efficacy and safety of anti-tumor necrosis factor alpha in very early onset inflammatory bowel disease

LV Collen, V Mitsialis, DY Kim… - Inflammatory Bowel …, 2023 - academic.oup.com
Background Very early onset inflammatory bowel disease (VEOIBD) is defined as disease
onset in patients younger than 6 years. Challenges in treatment of VEOIBD include lack of …

The future of advanced therapies for pediatric Crohn's disease

J Gallagher, JR Rosh, B Sahn - Pediatric Drugs, 2023 - Springer
Pediatric Crohn's disease commonly presents with moderate-to-severe intestinal
inflammation with a greater risk of complications if remission is not achieved. Anti-tumor …

Managing pediatric Crohn's disease: recent insights

K Baldwin, V Grossi, JS Hyams - Expert Review of …, 2023 - Taylor & Francis
Introduction Children and adolescents with Crohn's disease present unique challenges due
to extensive disease at diagnosis and the effect of bowel inflammation on growth. Historical …

Current role of monoclonal antibody therapy in pediatric IBD: A special focus on therapeutic drug monitoring and treat-to-target strategies

M Claßen, A Hoerning - Children, 2023 - mdpi.com
In the last two decades, biologicals have become essential in treating children and
adolescents with inflammatory bowel disease. TNF-α inhibitors (infliximab, adalimumab and …